#ESMODailyReporter👉
LightNews LightNews
myesmo.bsky.social
📌@mdcurioni.bsky.social discusses the challenges of overcoming acquired resistance to #immunotherapy in #NSCLC, highlighting some positive and negative trial data from #ELCC26. Learn more in the #ESMODailyReporter 👉 https://ow.ly/f7WB50YA1b0

March 28, 2026 at 9:05 AM
myesmo.bsky.social
The groundbreaking work behind the development of TCR mimics − ‘minibinders’ − is described by Sine Reker Hadrup in her Keynote Lecture at #ESMOImmuno25 and in an Opinion piece in the #ESMODailyReporter #ImmunoOncology
👉 https://ow.ly/jH9x50XHyFI
December 12, 2025 at 10:20 AM
myesmo.bsky.social
#ESMOImmuno25 Awardee, Ignacio Melero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter 👉 https://ow.ly/bgun50XGRUt

December 10, 2025 at 2:32 PM
myesmo.bsky.social
Novel approaches are needed to address the general wellbeing of patients with cancer. Studies presented at #ESMO25 add to growing evidence supporting the use of #DigitalTools.
Find out more in the #ESMODailyReporter 👉 https://ow.ly/uSpY50XjC7Q

#CancerCare #DigitalHealth
October 31, 2025 at 11:10 AM
myesmo.bsky.social
#ESMO25: Arthur Braat discusses the use of radiopharmaceuticals in advanced gastroenteropancreatic neuroendocrine tumours (#NETs) with reference to several studies presented in Berlin. Read more in the #ESMODailyReporter 👉 https://ow.ly/G5yW50XjyWv

#RareCancers
October 30, 2025 at 10:10 AM
myesmo.bsky.social
📊 Managing complex #RWD is key to advancing patient care and research.

#AI and digital tools help clean and standardise clinical data, turning it into actionable insights for smarter, data-driven decisions

#ESMODailyReporter 👉 dailyreporter.esmo.org/esmo-congres...

#AIOncology #ESMOAI25
October 29, 2025 at 8:13 AM
myesmo.bsky.social
📊 Oncology professionals increasingly encounter outputs from Large Language Models (LLMs), which can support decision-making, reduce administrative tasks, and assist patient engagement.

Read more #ESMODailyReporter 👉 dailyreporter.esmo.org/esmo-congres...

#DigitalOncology #AIOncology #ESMOAI25
October 24, 2025 at 6:58 AM
myesmo.bsky.social
#ESMO25: Are personalised #CancerVaccines the next frontier or an elusive goal? Catherine Wu discusses the exciting potential of genomics-guided personalised vaccines and some of the related challenges.
#ESMODailyReporter 👉 https://ow.ly/aMxi50Xgn37

#ImmunoOncology
October 23, 2025 at 10:25 AM
myesmo.bsky.social
#ESMO25: Treatment optimisation to minimise harm without compromising efficacy is a clinical imperative. Elena Castro explains how existing therapies may be refined using technological advances to challenge current paradigms.
#ESMODailyReporter 👉 https://ow.ly/AsOy50XeZUz
October 20, 2025 at 4:02 PM
myesmo.bsky.social
#ESMO25: Positive change may be on the horizon for #UvealMelanoma. Roger Olofsson Bagge discusses how novel strategies are offering the possibility of extended patient survival and may be practice-changing.
#ESMODailyReporter 👉https://ow.ly/gQL050XeZAo

#immunotherapy
October 20, 2025 at 3:35 PM
myesmo.bsky.social
#ESMO25: Survival benefits with #ADCs sacituzumab govitecan and datopotamab deruxtecan in #ClinicalTrials of #TNBC support a potential shift in first-line treatment for PD-L1-negative, advanced TNBC.
Read more in the #ESMODailyReporter👉 dailyreporter.esmo.org/esmo-congres...

#BreastCancer
October 20, 2025 at 8:30 AM
drjorgebarriuso.bsky.social
An amazing discussion by Dr Sharlene Gill on the updates of CHECKMATE 8HW and BREAKWATER.

👉 Can we identify patients deriving benefit from single agent IO in MMRd /MSI-H metastatic CRC?
👉Is there any room to rechallenge in BRAF mCRC?

#ESMODailyReporter @myesmo.bsky.social
October 20, 2025 at 7:58 AM
myesmo.bsky.social
#ESMO25: Potentially practice-changing data with novel #immunotherapy combinations address unmet needs in #LiverCancers.
Read more in the #ESMODailyReporter 👉 https://ow.ly/UZPJ50XeKCE

Lorenza Rimassa
#HepatocellularCarcinoma #HCC
October 20, 2025 at 6:44 AM
myesmo.bsky.social
#ESMO25: Clinically relevant survival benefits reported in platinum-resistant #OvarianCancer with pembrolizumab plus weekly paclitaxel with or without bevacizumab in ENGOT-ov65/KEYNOTE-B96 #ESMODailyReporter 👉https://ow.ly/MIjA50XeuR3

#immunotherapy
October 18, 2025 at 4:01 PM
myesmo.bsky.social
#ESMO25: Disappointing results with #immunotherapy in head and neck cancer (#HNSCC) may be related to tumour heterogeneity. Sandra Schmitz considers how researchers can learn from disease biology to improve #ClinicalTrial design
#ESMODailyReporter 👉 https://ow.ly/EGlK50XesEz
October 18, 2025 at 9:10 AM
myesmo.bsky.social
#ESMO25: Thymus health appears to play a pivotal role in response to #immunotherapy. High vs low thymic health, assessed by an #AI-derived algorithm, was associated with improved survival in a cohort of patients treated with immunotherapy.
#ESMODailyReporter 👉 https://ow.ly/rk4P50XesEk

October 18, 2025 at 8:35 AM
myesmo.bsky.social
Data presented at #ESMO25 in extensive-stage #SCLC suggest new #ImmunoOncology combinations for first-line therapy (with tarlatamab) and maintenance treatment (with ceralasertib) may be on the horizon.
Read more in the #ESMODailyReporter 👉 https://ow.ly/Pwlf50XeswA

#LungCancer
October 18, 2025 at 7:10 AM
myesmo.bsky.social
#ESMO25: What is the clinical value of #GenomicProfiling in #RareCancers? Timothée Olivier discusses how comprehensive and prospective data are required to support wider implementation.
#ESMODailyReporter 👉 https://ow.ly/FwY550Xesut

#PrecisionOncology
October 18, 2025 at 6:45 AM
myesmo.bsky.social
#ESMO25: NorthStar #ClinicalTrial shows improved PFS with local consolidative therapy (LCT) added to osimertinib in metastatic EGFR-mutant #NSCLC, suggesting a role for LCT to extend disease control #ESMODailyReporter
👉https://ow.ly/V63o50Xe8Y7

#LungCancer
October 17, 2025 at 2:30 PM
myesmo.bsky.social
#ESMO25: Is less more for patients with #GuCancers? Christoph Oing discusses promising treatment optimisation strategies to improve patient-centred endpoints and reduce therapy burden in #ProstateCancer and #UrothelialCancer.
#ESMODailyReporter 👉 https://ow.ly/hqih50Xe38b
October 17, 2025 at 12:20 PM
myesmo.bsky.social
#ESMO25: Glenda Ramos Martínez receives the first ESMO Oncologist of the Year Award for her pioneering role as the first female medical oncologist in Ecuador and outstanding advocacy to improve access to #CancerTreatments
#ESMODailyReporter👉 https://ow.ly/A3XL50XcYfo
October 17, 2025 at 11:15 AM
myesmo.bsky.social
📊 Oncologists don’t need to be #AI experts, but they should understand how AI makes predictions and its limits. ESMO President Fabrice André calls for education & interdisciplinary collaboration to improve patient care.

#ESMODailyReporter 👉 buff.ly/wei558Y

#HealthAI #ESMOAI25
October 8, 2025 at 7:00 AM
myesmo.bsky.social
🤖 Multimodal foundation models integrate EHRs, genomics, imaging & patient-reported outcomes to help clinicians interpret #AIOncology
#ESMODailyReporter 👉 dailyreporter.esmo.org/news/ai-appl...
#DigitalOncology #ESMOAI25
October 2, 2025 at 6:52 AM
myesmo.bsky.social
🤖 Understanding #AI & patient-reported data is key in oncology. Remote patient monitoring gathers #RWD via apps & wearables. AI turns it into insights for earlier interventions & better care
#ESMODailyReporter 👉 sl1nk.com/qA8Vr

#HealthAI #DigitalOncology #ESMOAI25
September 27, 2025 at 7:13 AM
myesmo.bsky.social
In the Diary of an Oncology Leader video series by #ESMOW4O Marina Chiara Garassino shares the key lessons that continue to influence her leadership style.

👉 Stay tuned for the next episode featuring Angela Lamarca.

🔗 buff.ly/TgyUHbK

#ESMODailyReporter #GenderEquity #OncologyLeadership #W4O
July 15, 2025 at 12:02 PM